OncoVerity, Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

Phase 11

By Therapeutic Area

top 2

Oncology

150%

Hematology

150%

R&D Momentum

23/100

Pipeline Velocity

0/100

Trial Completion Rate

100/100

Pipeline Concentration

50/100

Pipeline Freshness

48/100

Strategic Signals

↗Active in Oncology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jul 22, 2024TrialA Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Mar 25, 2020TrialA Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Dec 23, 2019TrialCusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Jul 29, 2019TrialA Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Jun 29, 2017FDATrelstar — TRIPTODUR KIT

Dec 1, 2016TrialA Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

TrelstarJun 30, 2029

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Regulatory

Regulatory Timeline

20001 event

FDAJun 15

Trelstar — TRELSTAR

Application NDA020715 (NDA)

20011 event

FDAJun 29

Trelstar — TRELSTAR

Application NDA021288 (NDA)

20101 event

FDAMar 10

Trelstar — TRELSTAR

Application NDA022437 (NDA)

20171 event

FDAJun 29

Trelstar — TRIPTODUR KIT

Application NDA208956 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)